Medivir
Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.
MVIR | ST
Overview
Corporate Details
- ISIN(s):
- SE0000325151 (+4 more)
- LEI:
- 549300VWDGUX0WMJ1T79
- Country:
- Sweden
- Address:
- Box 1086, 141 22 Huddinge
- Website:
- https://www.medivir.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Medivir is a clinical-stage pharmaceutical company focused on developing innovative treatments for cancer. The company concentrates its research and development on oncology, specifically targeting cancers with high unmet medical needs where patients have few therapeutic options. Medivir's business strategy relies heavily on collaborations with academic and industrial partners to leverage specialized knowledge and advance its projects. Through this partnership-driven approach, the company has previously succeeded in taking products from research through clinical development to global launch. Its pipeline includes the development of novel tumor-directed therapies such as oral prodrugs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-08 09:15 |
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Medivir AB (publ)
|
Swedish | 80.7 KB | ||
| 2025-10-08 09:15 |
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting of Medivir AB (publ)
|
English | 82.0 KB | ||
| 2025-10-08 08:52 |
Share Issue/Capital Change
Medivir beslutar om en fullt garanterad företrädesemission motsvarande cirka 15…
|
Swedish | 81.6 KB | ||
| 2025-10-08 08:52 |
Share Issue/Capital Change
Medivir announces a fully guaranteed rights issue of approximately SEK 151 mill…
|
English | 81.3 KB | ||
| 2025-08-21 08:30 |
Interim Report
|
Swedish | 392.4 KB | ||
| 2025-08-21 08:30 |
Interim Report
|
English | 331.5 KB | ||
| 2025-05-07 15:30 |
Post-Annual General Meeting Information
Resolutions at the Annual General Meeting in Medivir on 7 May 2025
|
English | 40.6 KB | ||
| 2025-05-07 15:30 |
Post-Annual General Meeting Information
Beslut vid årsstämma i Medivir den 7 maj 2025
|
Swedish | 40.8 KB | ||
| 2025-04-29 08:30 |
Quarterly Report
|
Swedish | 395.9 KB | ||
| 2025-04-29 08:30 |
Interim Report
|
English | 337.0 KB | ||
| 2025-02-25 11:24 |
Major Shareholding Notification
|
Swedish | 9.1 KB | ||
| 2025-02-18 08:30 |
Annual Report
|
Swedish | 410.1 KB | ||
| 2025-02-18 08:30 |
Earnings Release
|
English | 339.3 KB | ||
| 2025-02-03 10:37 |
Major Shareholding Notification
|
Swedish | 9.1 KB | ||
| 2025-02-01 11:01 |
Major Shareholding Notification
|
Swedish | 8.9 KB |
Automate Your Workflow. Get a real-time feed of all Medivir filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Medivir via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-05-10 | Uli Hacksell | Other | Buy | 24,978 | 192,274.70 SEK |
| 2021-05-07 | Uli Hacksell | Other | Buy | 25,022 | 193,031.97 SEK |
| 2021-03-16 | Bengt Julander | Other | Other | 3,600,000 | 27,828,000.00 SEK |
| 2021-03-05 | Magnus Christensen | Other | Buy | 3,956 | 33,626.00 SEK |
| 2021-03-05 | Magnus Christensen | Other | Buy | 2,044 | 17,435.32 SEK |
| 2021-03-05 | Helena Levander | Other | Buy | 24,390 | 207,315.00 SEK |
| 2021-03-04 | Helena Levander | Other | Buy | 17,868 | 151,878.00 SEK |
| 2021-03-03 | Helena Levander | Other | Buy | 242 | 2,057.00 SEK |
| 2021-03-01 | Yilmaz Mahshid | Other | Buy | 25,000 | 217,250.00 SEK |
| 2021-02-19 | Bengt Julander | Other | Other | 223,606 | 1,565,242.00 SEK |
